文献速递新发突发、热带与寄生虫病

诺氏疟原虫与恶性疟原虫对抗疟药物敏感性的比较

Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本研究优化了诺氏疟原虫体外药敏试验方案,并与恶性疟原虫在相同条件下对比。SYBR Green I 荧光法最稳健。诺氏疟原虫对二氢叶酸还原酶抑制剂的敏感性显著高于恶性疟原虫,但对 blasticidin、DSM1 及二氢乳清酸脱氢酶抑制剂的敏感性较低。

要点

  • SYBR Green I 荧光法适用于诺氏疟原虫体外药敏检测。
  • 诺氏疟原虫对乙胺嘧啶、环氯胍和甲氧苄啶的敏感性高于恶性疟原虫。
  • 诺氏疟原虫对 blasticidin、DSM1 及二氢乳清酸脱氢酶抑制剂的活性较低。

核心结论

  • 诺氏疟原虫与恶性疟原虫对抗疟药物的敏感性存在种间差异。
  • 验证的荧光检测系统可用于筛选抗非恶性疟原虫疟疾的研究性化合物。

研究设计与样本

  • 体外药敏试验研究,比较诺氏疟原虫与恶性疟原虫在相同测试条件下的药物敏感性。
  • 采用 SYBR Green 荧光法或乳酸脱氢酶比色法监测诺氏疟原虫体外生长。

主要发现

  • SYBR Green I 法在诺氏疟原虫一个(27 h)或两个(54 h)生命周期中均为最稳健的检测格式。
  • 诺氏疟原虫对乙胺嘧啶、环氯胍和甲氧苄啶的敏感性显著高于恶性疟原虫。
  • 诺氏疟原虫对转染用选择剂 blasticidin 和 DSM1 的敏感性低于恶性疟原虫。
  • 二氢乳清酸脱氢酶抑制剂对诺氏疟原虫的活性较低。

临床怎么用

  • 诺氏疟原虫体外药敏数据可为临床用药提供参考,但需结合临床证据。
  • 该检测系统可用于评估研究性化合物对非恶性疟原虫疟疾的活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The simian malaria parasite Plasmodium knowlesi is now a well-recognized pathogen of humans in South-East Asia. Clinical infections appear adequately treated with existing drug regimens, but the evidence base for this practice remains weak. The availability of P. knowlesi cultures adapted to continuous propagation in human erythrocytes enables specific studies of in vitro susceptibility of the species to antimalarial agents, and could provide a surrogate system for testing investigational compounds against Plasmodium vivax and other non-Plasmodium falciparum infections that cannot currently be propagated in vitro. OBJECTIVES: We sought to optimize protocols for in vitro susceptibility testing of P. knowlesi and to contrast outputs with those obtained for P. falciparum under comparable test conditions. METHODS: Growth monitoring of P. knowlesi in vitro was by DNA quantification using a SYBR Green fluorescent assay or by colorimetric detection of the lactate dehydrogenase enzyme. For comparison, P. falciparum was tested under conditions identical to those used for P. knowlesi. RESULTS: The SYBR Green I assay proved the most robust format over one (27 h) or two (54 h) P. knowlesi life cycles. Unexpectedly, P. knowlesi displays significantly greater susceptibility to the dihydrofolate reductase inhibitors pyrimethamine, cycloguanil and trimethoprim than does P. falciparum, but is less susceptible to the selective agents blasticidin and DSM1 used in parasite transfections. Inhibitors of dihydroorotate dehydrogenase also demonstrate lower activity against P. knowlesi. CONCLUSIONS: The fluorescent assay system validated here identified species-specific P. knowlesi drug susceptibility profiles and can be used for testing investigational compounds for activity against non-P. falciparum malaria.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. van Schalkwyk DA, Moon RW, Blasco B, et al. Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents. J Antimicrob Chemother. 2017. PMID: 28961865. doi:10.1093/jac/dkx279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。